Cancer News and Research

Latest Cancer News and Research

EMEA grants orphan drug designation for pixantrone in Europe

Cell Therapeutics, Inc. ("CTI") announced today that the European Medicines Agency (EMEA) has granted pixantrone orphan drug designation for the treatment of DLBCL which accounts for about 80% of aggressive non-Hodgkin's lymphoma.

21 Dec 2009

Vitamin D rich food source for winter - Wild Alaska salmon

Today is the shortest day of the year. During the dark winter months, sunlight can be an insufficient source of vitamin D which is vital for the absorption of calcium and phosphorous. Low vitamin D levels have recently been linked to a greater chance of developing diseases including diabetes and heart disease, several cancers and the common cold.

21 Dec 2009

Researchers follow steps that lead some tumor cells to establish metastases

Up to 25% of cancer patients develop metastases in the brain - often long after successful treatment of the primary tumor. In almost all such cases, the prognosis is poor. The mechanisms responsible for the appearance of brain metastases have long been mysterious.

21 Dec 2009

United States Congress approves additional $15 million in research funding for lung cancer

Today, the United States Congress approved an additional $15 million in research funding for lung cancer as part of the fiscal year 2010 Department of Defense (DOD) Appropriations package.

20 Dec 2009

Medical physicists converge at ProCure TDC for training in physics of protons and proton therapy

Medical physicists from around the world converged at the ProCure Training and Development Center (TDC) last week for intense training in the physics of protons and proton therapy, an alternative to X-ray radiation for cancer treatment that spares healthy tissue and results in far fewer short- and long-term treatment side effects.

19 Dec 2009

Ontario surpasses federal target for radiation therapy

For the past 12 months, Ontario has surpassed the federal target for radiation therapy wait times, demonstrating that the province has continued to improve access to this important cancer treatment.

19 Dec 2009

Research lays hope for developing drugs that can control apoptosis

Walter and Eliza Hall Institute scientists have identified a key step in the biological process of programmed cell death, also called apoptosis.

19 Dec 2009

Charles Sherr awarded distinction of AAAS Fellow

Charles Sherr, M.D., Ph.D., co-chair of Genetics and Tumor Cell Biology at St. Jude Children's Research Hospital and a Howard Hughes Medical Institute Investigator, has been awarded the distinction of American Association for the Advancement of Science (AAAS) Fellow. AAAS is the world's largest general scientific society.

19 Dec 2009

Raptor Pharmaceutical enters into definitive agreements with institutional investors to purchase 3.7M units

Raptor Pharmaceutical Corp., today announced that it has entered into definitive agreements with institutional investors to purchase 3,747,558 units for gross proceeds of approximately $7.5 million, before placement agent fees and offering expenses.

19 Dec 2009

SCCA's infection control program leads to suppression of potential H1N1 pandemic

Despite a 100-fold increase in H1N1 influenza cases in the Seattle area during spring 2009, an aggressive infection control program to protect immunocompromised cancer patients and thorough screening measures resulted in no corresponding increase in H1N1 cases among the total patient population at the Seattle Cancer Care Alliance, according to a new study by researchers and physicians at Fred Hutchinson Cancer Research Center and the SCCA.

19 Dec 2009

Possible link between presence of breast cancer genes and infertility discovered

A New York Medical College physician who specializes in restoring or preserving fertility in female cancer patients has discovered a possible link between the presence of breast cancer genes and infertility.

19 Dec 2009

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

Doctors and researchers from the John Theurer Cancer Center at Hackensack University Medical Center recently presented research updates and clinical trial results of more than 20 innovative studies at the American Society of Hematology (ASH) annual meeting from December 5-8, 2009.

18 Dec 2009

UVA acquires Extend to broaden the potential for Gamma Knife Perfexion

Patients with overly large benign skull base tumors, lesions too close to critical anatomy and those with multiple brain metastases are among those who will benefit first from a new "frameless" device for use with Leksell Gamma Knife Perfexion systems.

From Elekta 18 Dec 2009

VA apologizes for faulty prostate-cancer program in Pa. but denies radiation violations

"The Department of Veterans Affairs yesterday apologized repeatedly for a prostate-cancer program that gave incorrect radiation doses to veterans for six years at its main Philadelphia hospital," The Philadelphia Inquirer reports.

18 Dec 2009

Tackle Cancer Foundation calls attention to REVLIMID for myeloma patients

The TACKLE CANCER FOUNDATION wants to call attention to important news for patients with the blood cancer multiple myeloma. A new study shows patients benefit from daily medical treatments to keep their cancer in check after they have had a stem cell (bone marrow) transplant. The current standard of care is to give patients the transplant and then hold off on additional treatment until they relapse. The new study shows continuous treatment with the oral drug REVLIMID following the transplant significantly prolongs remission, increasing time to disease progression.

18 Dec 2009

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

Celgene Corporation today announced the National Cancer Institute (NCI), a part of the National Institutes of Health, reported initial data from a Phase III, randomized, double-blind, multi-center clinical study led by the Cancer and Leukemia Group B (CALGB).

18 Dec 2009

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

18 Dec 2009

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the termination of its agreement with sanofi-aventis U.S. ( SNY) dated March 5, 2009 for the development, commercialization and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market, following the Company's announcement last week of the results for its European Phase 3 study for cetrorelix in BPH.

18 Dec 2009

Rosetta Genomics announces third-quarter 2009 financial results

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, today reported financial results for the three and nine months ended September 30, 2009 and provided a business update.

18 Dec 2009

ANIS2's second edition on ‘micro and nanotechnologies for cancer research’ is open for registrations

There is still time until January 8 2010 to register for the second edition of the Alp NanoBio International School (ANIS2), which will be held in Sterzing/Vipiteno (Bozen, Italy) from 11 to 15 of January 2010, organized by the Centre of Excellence LATEMAR - funded by MIUR, in collaboration with the Fondazione Bruno Kessler (FBK).

18 Dec 2009

Cancer News and Research

Latest Cancer News and Research

EMEA grants orphan drug designation for pixantrone in Europe

Vitamin D rich food source for winter - Wild Alaska salmon

Researchers follow steps that lead some tumor cells to establish metastases

United States Congress approves additional $15 million in research funding for lung cancer

Medical physicists converge at ProCure TDC for training in physics of protons and proton therapy

Ontario surpasses federal target for radiation therapy

Research lays hope for developing drugs that can control apoptosis

Charles Sherr awarded distinction of AAAS Fellow

Raptor Pharmaceutical enters into definitive agreements with institutional investors to purchase 3.7M units

SCCA's infection control program leads to suppression of potential H1N1 pandemic

Possible link between presence of breast cancer genes and infertility discovered

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

UVA acquires Extend to broaden the potential for Gamma Knife Perfexion

VA apologizes for faulty prostate-cancer program in Pa. but denies radiation violations

Tackle Cancer Foundation calls attention to REVLIMID for myeloma patients

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

Rosetta Genomics announces third-quarter 2009 financial results

ANIS2's second edition on ‘micro and nanotechnologies for cancer research’ is open for registrations

Cancer Research - Second Edition eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Newsletters you may be interested in